Is Quotient Limited (QTNT)’s Fuel For Real? The Stock Just Increased Again

February 21, 2018 - By Linda Rogers

Investors sentiment decreased to 1.42 in 2017 Q3. Its down 6.98, from 8.4 in 2017Q2. It worsened, as 7 investors sold Quotient Limited shares while 12 reduced holdings. 9 funds opened positions while 18 raised stakes. 21.37 million shares or 49.89% less from 42.64 million shares in 2017Q2 were reported.
Meeder Asset Mngmt reported 0% stake. New York-based Hudson Bay Cap Mngmt Limited Partnership has invested 0.01% in Quotient Limited (NASDAQ:QTNT). New York State Common Retirement Fund reported 13,700 shares stake. Royal Fincl Bank Of Canada stated it has 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). State Street Corporation, a Massachusetts-based fund reported 268,977 shares. Vanguard Grp Inc Inc owns 71,841 shares. State Board Of Administration Of Florida Retirement System holds 23,512 shares. Tower Cap Limited Liability (Trc) accumulated 0% or 6,359 shares. California State Teachers Retirement System stated it has 44,000 shares or 0% of all its holdings. Clearbridge Limited Co accumulated 1.67 million shares. Northern Tru accumulated 241,860 shares. Millennium Mgmt Ltd Liability Corporation holds 244,020 shares or 0% of its portfolio. Perceptive Advsrs Ltd Liability has invested 0.7% of its portfolio in Quotient Limited (NASDAQ:QTNT). Park West Asset Mngmt Lc invested in 270,034 shares. Sio Ltd Co stated it has 2.34 million shares or 6% of all its holdings.

Since September 15, 2017, it had 0 insider buys, and 2 sales for $904,595 activity.

The stock of Quotient Limited (NASDAQ:QTNT) is a huge mover today! The stock increased 7.40% or $0.31 during the last trading session, reaching $4.5. About 290,638 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 16.87% since February 21, 2017 and is downtrending. It has underperformed by 33.57% the S&P500.
The move comes after 5 months positive chart setup for the $205.15 million company. It was reported on Feb, 21 by Barchart.com. We have $4.91 PT which if reached, will make NASDAQ:QTNT worth $18.46 million more.

Analysts await Quotient Limited (NASDAQ:QTNT) to report earnings on May, 28. They expect $-0.51 EPS, up 26.09 % or $0.18 from last year’s $-0.69 per share. After $-0.47 actual EPS reported by Quotient Limited for the previous quarter, Wall Street now forecasts 8.51 % negative EPS growth.

Quotient Limited (NASDAQ:QTNT) Ratings Coverage

Among 3 analysts covering Quotient (NASDAQ:QTNT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quotient had 6 analyst reports since August 11, 2015 according to SRatingsIntel. UBS maintained Quotient Limited (NASDAQ:QTNT) rating on Wednesday, November 4. UBS has “Buy” rating and $26 target. The rating was maintained by BTIG Research with “Buy” on Tuesday, February 6. The stock has “Buy” rating by Jefferies on Wednesday, November 1. The rating was initiated by Jefferies on Tuesday, August 11 with “Buy”. The company was upgraded on Friday, August 14 by Zacks. BTIG Research initiated the stock with “Buy” rating in Thursday, August 31 report.

More news for Quotient Limited (NASDAQ:QTNT) were recently published by: Seekingalpha.com, which released: “Quotient Limited’s (QTNT) CEO Paul Cowan on Q2 2018 Results – Earnings Call …” on October 31, 2017. Globenewswire.com‘s article titled: “Quotient Limited to Report Continued Progress on the Commercial Scale-Up of …” and published on July 21, 2017 is yet another important article.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $205.15 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: